$213.9 M

IMPL Mkt cap, 19-Oct-2021
Impel NeuroPharma Net income (Q2, 2021)-15.5 M
Impel NeuroPharma EBIT (Q2, 2021)-14.9 M
Get notified regarding key financial metrics and revenue changes at Impel NeuroPharmaLearn more
Banner background

Impel NeuroPharma Income Statement

Quarterly

USDQ2, 2021

R&D expense

6.1m

General and administrative expense

8.9m

Operating expense total

14.9m

EBIT

(14.9m)

Pre tax profit

(15.5m)

Net Income

(15.5m)

Impel NeuroPharma Balance Sheet

Quarterly

USDQ2, 2021

Total Equity

216.3m

Impel NeuroPharma Cash Flow

Quarterly

USDQ2, 2021

Net Income

(26.8m)

Depreciation and Amortization

493.0k

Accounts Payable

1.1m

Cash From Operating Activities

(25.9m)

Purchases of PP&E

(116.0k)

Cash From Investing Activities

(116.0k)

Cash From Financing Activities

79.9m

Net Change in Cash

53.9m

Impel NeuroPharma Ratios

USDQ2, 2021

Impel NeuroPharma Employee Rating

4.211 votes
Culture & Values
4.2
Work/Life Balance
3.7
Senior Management
4.2
Salary & Benefits
3.7
Career Opportunities
4.1
Source